IL244693B - History of piperazine and their use as drugs - Google Patents

History of piperazine and their use as drugs

Info

Publication number
IL244693B
IL244693B IL244693A IL24469316A IL244693B IL 244693 B IL244693 B IL 244693B IL 244693 A IL244693 A IL 244693A IL 24469316 A IL24469316 A IL 24469316A IL 244693 B IL244693 B IL 244693B
Authority
IL
Israel
Prior art keywords
medicament
piperazine derivatives
piperazine
derivatives
Prior art date
Application number
IL244693A
Other languages
English (en)
Hebrew (he)
Other versions
IL244693A0 (en
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of IL244693A0 publication Critical patent/IL244693A0/en
Publication of IL244693B publication Critical patent/IL244693B/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL244693A 2013-10-16 2016-03-21 History of piperazine and their use as drugs IL244693B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13188904 2013-10-16
PCT/EP2014/072085 WO2015055698A1 (en) 2013-10-16 2014-10-15 Piperazine derivatives and the use thereof as medicament

Publications (2)

Publication Number Publication Date
IL244693A0 IL244693A0 (en) 2016-04-21
IL244693B true IL244693B (en) 2019-08-29

Family

ID=49354583

Family Applications (1)

Application Number Title Priority Date Filing Date
IL244693A IL244693B (en) 2013-10-16 2016-03-21 History of piperazine and their use as drugs

Country Status (21)

Country Link
US (1) US9233953B2 (enExample)
EP (1) EP3057963B1 (enExample)
JP (1) JP6483105B2 (enExample)
KR (1) KR102281284B1 (enExample)
CN (1) CN105636961B (enExample)
AR (1) AR098037A1 (enExample)
AU (1) AU2014336258B2 (enExample)
BR (1) BR112016008062B1 (enExample)
CA (1) CA2926754C (enExample)
CL (1) CL2016000884A1 (enExample)
DK (1) DK3057963T3 (enExample)
EA (1) EA029313B1 (enExample)
ES (1) ES2745555T3 (enExample)
HU (1) HUE047044T2 (enExample)
IL (1) IL244693B (enExample)
MX (1) MX370006B (enExample)
PH (1) PH12016500577A1 (enExample)
PL (1) PL3057963T3 (enExample)
TW (1) TW201609716A (enExample)
UY (1) UY35785A (enExample)
WO (1) WO2015055698A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106854189A (zh) * 2015-12-08 2017-06-16 湖南华腾制药有限公司 一种哌嗪化合物的合成方法
CN107778257A (zh) * 2016-08-29 2018-03-09 湖南华腾制药有限公司 一种哌嗪衍生物的合成方法
CN106977463A (zh) * 2017-05-31 2017-07-25 湖南华腾制药有限公司 一种联苯取代哌嗪衍生物的合成方法
CN107417679A (zh) * 2017-08-04 2017-12-01 河南农业大学 1,3‑唑类取代吡嗪类化合物的制备方法
KR20220125326A (ko) 2020-01-09 2022-09-14 디스크 메디슨, 인크. 적혈구형성 프로토포르피린증, x-연계된 프로토포르피린증, 또는 선천성 적혈구 조혈포르피린증을 글리신 운반 억제제로 치료하는 방법
CN117050051A (zh) * 2023-08-14 2023-11-14 上海药坦药物研究开发有限公司 一种2-溴-1-(5-碘噻吩-2-基)-乙酮的纯化方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0224084D0 (en) * 2002-10-16 2002-11-27 Glaxo Group Ltd Novel compounds
GB0505085D0 (en) * 2005-03-11 2005-04-20 Glaxo Group Ltd Compounds
CA2606288A1 (en) * 2005-04-18 2006-10-26 Neurogen Corporation Subtituted heteroaryl cb1 antagonists
TW201105674A (en) * 2009-07-08 2011-02-16 Leo Pharma As Novel JAK receptor and protein tyrosine kinase inhibitors and pharmaceutical use thereof

Also Published As

Publication number Publication date
TW201609716A (zh) 2016-03-16
CN105636961A (zh) 2016-06-01
IL244693A0 (en) 2016-04-21
AU2014336258A1 (en) 2016-04-14
KR20160062187A (ko) 2016-06-01
UY35785A (es) 2015-04-30
NZ718251A (en) 2021-02-26
EA029313B1 (ru) 2018-03-30
BR112016008062A2 (enExample) 2017-08-01
CN105636961B (zh) 2019-11-05
HUE047044T2 (hu) 2020-04-28
MX2016004847A (es) 2016-07-19
CL2016000884A1 (es) 2016-12-30
CA2926754C (en) 2021-09-14
PL3057963T3 (pl) 2019-12-31
KR102281284B1 (ko) 2021-07-23
JP6483105B2 (ja) 2019-03-13
CA2926754A1 (en) 2015-04-23
ES2745555T3 (es) 2020-03-02
WO2015055698A1 (en) 2015-04-23
AU2014336258B2 (en) 2018-07-12
PH12016500577B1 (en) 2016-06-20
US20150105397A1 (en) 2015-04-16
EP3057963B1 (en) 2019-06-19
US9233953B2 (en) 2016-01-12
EP3057963A1 (en) 2016-08-24
BR112016008062B1 (pt) 2022-11-16
DK3057963T3 (da) 2019-09-16
EA201600323A1 (ru) 2016-10-31
AR098037A1 (es) 2016-04-27
PH12016500577A1 (en) 2016-06-20
JP2016533368A (ja) 2016-10-27
MX370006B (es) 2019-11-28

Similar Documents

Publication Publication Date Title
IL264541B (en) The history of sulfamoylpyrrolamide and their use as drugs to treat jaundice b
IL242141B (en) The history of sulfamoylthiophenamide and their use as drugs to treat jaundice b
IL241110A0 (en) n-phenyl-carboxamide derivatives and their use as drugs for the treatment of type b jaundice
IL243042A0 (en) Consequences of aminotriazine and a pharmaceutical preparation containing it
SG11201507327TA (en) Pyrazole-amide compound and medicinal uses therefor
IL244214B (en) Thienopiperidine derivative and its use
GB201311361D0 (en) Compounds and their therapeutic use
PT3064491T (pt) Derivado de sulfonamida e sua utilização medicinal
IL244693A0 (en) History of piperazine and their use as drugs
GB201308736D0 (en) Compounds and their therapeutic use
EP3048886A4 (en) 3, 4-bis-benzylsulfonylbutanenitrile and its pharmaceutical use
EP3055286A4 (en) 4-methylsulfonyl-2-butenenitrile and its pharmaceutical use
AP2015008814A0 (en) Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
GB201303827D0 (en) The sleep easy
GB201307677D0 (en) Compounds and their therapeutic use

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed